Using the same cancer model, Zheng et al (168) investigated the novel STAT3 inhibitor, W2014-S, for its potential to enhance the efficacy of gefitinib and erlotinib in overcoming drug resistance in NSCLC. This evidence concerns the gene STAT3 and cancer.